
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KAN-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : DCVC Bio
Deal Size : $29.5 million
Deal Type : Funding
Kanvas Biosciences Raises $12.5M in Additional Funding
Details : The funding will be used to advance the development of the company's lead product KAN-001, which is being evaluated in the early-stage clinical trial studies for the treatment of neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 02, 2024
Lead Product(s) : KAN-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : DCVC Bio
Deal Size : $29.5 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Recipient : Federation Bio
Deal Size : Undisclosed
Deal Type : Acquisition
Details : As part of the asset acquisition, Kanvas Biosciences will advance two core initiatives that improve the treatment of prevalent diseases: Immuno-oncology program and Inflammatory Bowel Disease program.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 11, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Recipient : Federation Bio
Deal Size : Undisclosed
Deal Type : Acquisition
